Istesso provides updates on leramistat and next-generation programs
Advancement of leramistat, a first-in-class mitochondrial complex I modulator (MCM),...
26th November 2025Istesso is rethinking how we extend healthspan as we age. Rather than trying to stop or slow disease progression, we focus on restoring the body’s natural capacity to repair itself and return to health.
Our pioneering approach centers on mitochondrial Complex I modulators, or MCMs, a new class of oral small molecule drugs that repair and regenerate tissue across multiple organs and disease settings. Our lead clinical program, leramistat, is in Phase 2 trials, and we are expanding MCMs to other chronic diseases of aging with a pipeline of assets, each holding blockbuster potential.
"It’s hard to imagine anything more rewarding than translating exciting science into treatments with the potential to benefit patients."
Advancement of leramistat, a first-in-class mitochondrial complex I modulator (MCM),...
26th November 2025
Istesso’s new class of developmental drugs, which inhibit mitochondrial complex...
17th July 2025
Istesso, the leading adaptive tissue-repair company, is pleased to announce...
4th June 2025